Stephanie Devaney is the Deputy Director of the All of Us Research Program at the National Institutes of Health. Prior to this she led the coordination of the Precision Medicine Initiative from the Office of the Chief of Staff at the White House. In this role she coordinated the many components of the Initiative and guided the vision of the overall effort, along with the many federal partners. Before joining the White House, Stephane worked in the Office of the Director at the National Institutes of Health. Read her full bio.

Q&A with All of Us Research Program Deputy Director Stephanie Devaney, Ph.D.

Q1a: You are the Deputy Director of the All of Us Research Program. What is your role as the deputy director and why is this initiative so important?

A: As deputy director, my primary role is to work closely with the All of Us Director Eric Dishman in guiding the program from concept to reality. Our vision is to enable a healthier future for all of us by building a data resource that scientists can use to speed up research and the development of individualized approaches to prevention and treatment. To do this, we’ll collect different types of data from one million or more people over time. All kinds of researchers – from students to citizen scientists to established investigators – will be able to access the data for their studies. A core value of the program is partnering with participants, so we’re working with them to shape the program and to give them ways to learn about their own health. I’m proud to be a part of this extraordinary effort.

Q2a: The All of Us Research Program has opened enrollment in May of this year. What can an individual enrolling expect from this program?

A: Some participants might join through their health care provider organizations while others might sign up directly through JoinAllofUs.org or our app. Everyone who joins will go through a consent process to be sure participants are well-informed about the program before they join. If they say yes, they’ll be invited to do other activities. These could include answering surveys, giving blood and urine samples, and even sharing data from wearable devices. We’ll also ask participants to give access to their electronic health records, which are an essential component of the data we’re collecting.

The information participants choose to share will flow into the data resource that researchers can use to study many different topics in health and disease. Participants will also have access to their own information. We’ll be piloting ways to return this information to them responsibly and thoughtfully.

We also ask our participants for feedback on their experience in the program so that we can make adjustments based on input. Our program is focused on using a user-centered design approach, which means being in touch with our participants and other stakeholders, such as researchers. To take this one step further, we have opportunities for participants to engage in the planning and design of the study–already many actual participants are part of our leadership committees.

All of Us is a long journey, and we hope to collect data from participants over decades. The more information participants share, the more they may learn about themselves. Of course, participants can choose to withdraw at any time, and we will always respect their decision.

Q2b: What is the role of my primary physician in this process?

A: All of Us is working with providers from across the country to ensure that they understand the research program and are prepared to help their patients make a decision about enrolling. We will continue to engage with all types of providers as the program continues to grow. However, this is a research program and doesn’t necessarily work directly with participants’ primary physician. We do not share any information with participants’ providers or others in their lives. We are working on ways to make it easier for participants to share what they learn from All of Us with their providers, if they so choose.

Q2c: Will the generated data be part of my regular health record or held exclusively within the All of Us Research Program database?

A: (See previous response)

Q2d: How can I ensure that this data is protected and secure?

A: All of Us takes data privacy and security very seriously. Our Director, Eric Dishman, just wrote an op-ed on this very topic, as we know this is top of mind for most people as they try to make a decision about enrolling.

Any time you share information, there is a risk, but we have taken many steps to keep participants’ data safe. Here are a few of them:

  • All of Us has a Certificate of Confidentiality from the U.S. government. This helps the program fight legal demands (such as a court order) to give out information that could identify participants.

  • We use the best available security technologies and are constantly testing and monitoring our systems to find and improve any weak points.

  • Participant data is stored on protected computers. We limit and track who can access this data.

  • We remove names and other direct identifiers (like Social Security numbers) from participant records and replace them with codes. There is a master list linking codes to names. This list is kept secure, and very few people have access to it.

  • Researchers who want to access the database are required to sign an agreement stating that they will not attempt to identify any participants.

  • Participants will be notified if there is a breach that compromises their data.

You can read more about our efforts to safeguard participant data in our Privacy and Trust Principles and Data Security Policy and Framework.

Q2e: How do you ensure that all socio-economic levels, races, and ethnicities are properly represented within the test population?

A: Achieving a demographically, geographically, and medically diverse participant community is a top priority for us. That’s because data from a diverse participant community will fill gaps in our scientific knowledge and give everyone the chance to benefit from biomedical research. We’ve spent the last year building relationships from coast to coast with partners who can help us reach diverse communities. These communities include people who haven’t taken part in research—often because they’ve never been asked—or may be hesitant to. Our partners are helping us build trust in these communities and educate them about the value of research and the role of the All of Us Research Program in creating a healthier future for all of us.

Q2f: By when do we expect we will have enrolled one million participants?

A: We estimate that enrolling and collecting data from one million people will take about five to six years, but this depends on a lot of things. The scale and scope of this study and the design make it unique. We’ll be learning a lot as we go. We’re very happy with how enrollment is going so far, and we expect these numbers to continue to increase.

Q2g: By when do you expect we can start to harvest some of the learnings from this initiative?

A: The data resource is under construction now and will launch within the next year, when it has enough initial data to be useful for research. The resource will grow quickly as more participants enroll and contribute data. We expect that within just a few years, it could be used to study complex risk factors, support ancillary studies and clinical trials, and link to other large data sets.

Q2h: By when will we see a more established change and broader adoption of precision medicine in the clinic because of this initiative?

A: We can’t know for sure when outcomes from the All of Us Research Program will translate into changes in clinical care, but we’re optimistic that the program has a lot to offer in that regard.

Q2i: By when can we expect new treatments or preventions as a result of this initiative?

A: I wish we could predict medical advances, but there’s no crystal ball. We do know that for so many medical breakthroughs and precision medicine research questions, large and diverse cohorts are essential; data has been too siloed with limited access to some of our brightest minds. We will only start to answer some of the most vexing questions about human health when we start sharing more data, engage participants as partners, and open access to all sorts of researchers to work as teams on a rich data set.

Q2j: The data to be collected will be enormous. What approach will be taken to manage, understand, and share the data and findings?

A: We’re building what may be one of the largest datasets in human history and making it accessible to a broad swath of researchers, from citizen scientists to scientists with lots of experience in biomedical research in academia, the private sector, and from all parts of the globe, offering them clean, curated, rich data from a huge, diverse cohort. To get access, researchers will need to get approved (we’ll approve the researcher, not the project), abide by a code of conduct, prove their identity, take ethics training, and agree to describe all of the projects they start up once they have access to the data.

Only researchers approved by the All of Us Research Program will be allowed to see data from individual participants. Researchers who can see individual participant data will not be able to see names or other information that could identify someone directly.

We’ll maintain a public list on the All of Us website of every researcher accessing the data resource so participants can see who’s using their data and how.

Q2k: What research groups, commercial entities, and other organizations will be involved in data/knowledge extraction of this large project?

A: (See previous response)

Q3a: There are many global large scale initiatives - the UK-based 100,000 Genomics England Project, the Chinese Precision Medicine Initiative, and the France Genome Medicine Plan, just to name a few. Will there ever be an effort that combines some of those data and insights from these separate initiatives?

A: We’ve learned a lot from these efforts. We’ve been actively involved in meetings with international and domestic cohort studies. Advances in precision medicine will depend on leveraging all of them, including the data they’ve collected and the insights they’ve gathered. We believe it’s better to have more data and more collaborations and will be looking for opportunities to partner.

Q3b: What would be required to achieve this?

A: There’s so much we want to do, and creating a roadmap for these collaborative opportunities is one of them. Right now, though, we’re really focused on continuing to excite and engage potential participants about the program. The data they share will make everything else possible.

Q4: Is there anything else you would like to add?

A: Every element of the All of Us Research Program is carefully considered and evidence based. We’re currently working on developing a set of scientific priorities to help determine which kinds of data to collect and how. We’ve solicited ideas from the scientific community, participants, and the public to ensure that what we do can be useful and meaningful for researchers and, eventually, health care.

Interview with Gabriel Bien-Willner of Palmetto GBA

Q: What does your role entail as the director of the MolDX program at Palmetto GBA?

A: The job directing MolDX is multifaceted; first and foremost the MolDX program is responsible for assessing molecular diagnostic tests on the market and makes coverage and pricing determinations for such tests and technology. This is usually done through local coverage determination policies or technical assessments.

Read More

Interview with Peter Marks of FDA

Q: The CBER’s Regenerative Medicine Advanced Therapy Designation program has been very successful, with about 100 requests for designation in the two years of its existence. Can you please tell us about the program and how it was put together?

A: The Regenerative Medicine Advanced Therapy (RMAT) Designation program came into being as part of the 21st Century Cures Act that was signed into law on December 13, 2016.

Read More

Interview with Calum MacRae of Harvard Medical School

Q: What patient data do we need to better understand the underlying cause of disease and how to prevent it?

A: Medicine at present is highly underdetermined and data poor. To be precise, one must be comprehensive, so medicine (with our consent) will use not only what we currently conceive of as biomedical information, but also data from across our lives.

Read More

Headlines from PMWC 2019 Silicon Valley

A big ‘Thank You’ to all of our presenters and attendees for celebrating 10 years of precision medicine progress with us! PMWC 2019 Silicon Valley was attended by 2000 participants from 35 countries, which included over 400 speakers in 5 parallel tracks!

Read More

Interview with Ken Bloom of Ambry Genetics

Q: Tell us more about your organization/company. What patient population are you serving and which services are you specializing in?

A: Ambry Genetics is a recognized leader in high quality complex genetic testing. We seek to find the genomic cause or contributors to rare diseases, abnormal phenotypes and hereditary disorders.

Read More

Interview with Lee Pierce of Sirius Computer Solutions

Q: What is the state of big data and analytics in healthcare, and how to best use the reams of data available?

A: More than ever, Healthcare organizations are achieving measurable value through use of their data and analytics assets. There is more raw material available than ever to create value. This raw material is the data flowing from internal systems and applications and also from devices and systems external to healthcare organizations.

Read More

Interview with Anita Nelsen of PAREXEL

Q: There are various new, emerging technologies that bring us closer towards a cure for life-threatening disorders such as cancer, HIV, or Huntington’s disease. Prominent examples include the popular gene editing tool CRISPR or new and improved cell and gene therapies. By when can we expect these new technologies being part of routine clinical care?

A: Today’s emerging technologies are making the promise of individualized treatment a reality.

Read More

Interview with Ilan Kirsch of Adaptive Biotechnologies

Q: The Nobel Prize in Medicine was awarded recently to James Allison and Tasuku Honjo for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” What is your first-hand experience the impact that those new drugs had on patients?

A: For decades cancer was viewed as solely a cell-autonomous condition.

Read More

BMS buys Celgene | Lilly buys Loxo Oncology – Does this Signal a Return to Strong Deal-Making Activities in 2019?

Bristol-Myers Squibb’s blockbuster $74B deal to buy Celgene creates an oncology powerhouse amid industrywide excitement about the rapidly evolving science and explosive growth of the sector. The agreement could signal a return to deal-making for the pharmaceutical industry in the $133B global oncology therapeutics market.

Read More

Interview with Gini Deshpande of NuMedii

Q: What need is NuMedii addressing?

A: NuMedii, has been pioneering the use of Big Data, artificial intelligence (AI) and systems biology since 2010 to accelerate the discovery of precision therapies to address high unmet medical needs. Artificial Intelligence approaches are a natural fit to harness Big Data as they provide a framework to ‘train’ computers to recognize patterns and sift through vast amounts of new and existing genomic

Read More

Interview with Minnie Sarwal of UCSF

Q: Genomic medicine is entering more hospitals and bringing with it non-invasive technology that can be used to better target and treat diseases. What are some key milestones that contributed to this trend?

A: Completion of complete sequence data from the human genome project, and the advances in proteomic, microRNA and epigenetic assays added a layer of pathway biology to the understanding of human diseases.

Read More

Interview with Shidong Jia of Predicine

Q: Once sequencing has been validated as a clinical solution via trusted workflows, and coinciding with the technological developments driving costs lower, we can expect accelerated human genome profiling for clinical Dx. How soon, do you think, will we see accelerated growth and what can we expect?

A: We will see accelerated human genome profiling for clinical Dx in 2019 and the coming years as more biomarker-based cancer drugs are gaining approval.

Read More

Interview with Iya Khalil of GNS Healthcare

Q: Artificial intelligence (AI) techniques have sent vast waves across healthcare, even fueling an active discussion of whether AI doctors will eventually replace human physicians in the future. Do you believe that human physicians will be replaced by machines in the foreseeable future? What are your thoughts?

A: I think that there’s a lot of speculation and uncertainty around AI, but I don’t foresee a time when we won’t need physicians.

Read More

Interview with Ilya Michael Rachman of Immix Biopharma Inc.

Q: The Nobel Price in Medicine was awarded recently to James Allison and Tasuku for their work on unleashing the body’s immune system to attack cancer, a breakthrough that has led to an entirely new class of drugs and brought lasting remissions to many patients who had run out of options. The Nobel committee hailed their accomplishments as establishing “an entirely new principle for cancer therapy.” Besides CAR T-cell therapy what do you think next generation immunotherapies will look like to successfully combat cancer?

A: The next generation of immunotherapies will build on the insights discovered by immunologists like James Allison and Tasuku Honjo and extend them to modify the body’s response to tumors.

Read More

Join me to Kick off PMWC Silicon Valley in the Santa Clara Convention Center, Focusing on Every Element of Precision Medicine

My team worked in collaboration with Bill Dalton, Kim Blackwell, Atul Butte / India Hook Barnard, Nancy Davidson and Sharon Terry to create a program that touches every component of precision medicine while bringing together all of its key stakeholders. Leading participating institutions including Stanford Health Care, UCSF, Duke Health, Duke University, John Hopkins University, University of Michigan and more will share their learnings and experiences and their successes and challenges, as they make precision medicine the new standard of care for all.

Read More
Johns Hopkins
University Of Michigan

The Precision Medicine World Conference (PMWC), in its 17th installment, will take place in the Santa Clara Convention Center (Silicon Valley) on January 21-24, 2020. The program will traverse innovative technologies, thriving initiatives, and clinical case studies that enable the translation of precision medicine into direct improvements in health care. Conference attendees will have an opportunity to learn first-hand about the latest developments and advancements in precision medicine and cutting-edge new strategies and solutions that are changing how patients are treated.

See 2019 Agenda highlights:

  • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • AI & Data Science Showcase
    • Clinical & Research Tools Showcase
    • Clinical Dx Showcase
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Digital Health/Health and Wellness
    • Digital Phenotyping
    • Diversity in Precision Medicine
    • Drug Development (PPPs)
    • Early Days of Life Sequencing
    • Emerging Technologies in PM
    • Emerging Therapeutic Showcase
    • FDA Efforts to Accelerate PM
    • Gene Editing
    • Genomic Profiling Showcase
    • Immunotherapy Sessions & Showcase
    • Implementation into Health Care Delivery
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Microbial Profiling Showcase
    • Microbiome
    • Neoantigens
    • Next-Gen. Workforce of PM
    • Non-Clinical Services Showcase
    • Pharmacogenomics
    • Point-of Care Dx Platform
    • Precision Public Health
    • Rare Disease Diagnosis
    • Resilience
    • Robust Clinical Decision Support Tools
    • Wellness and Aging Showcase

See 2019 Agenda highlights:

    • Five tracks will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • AI & Data Science Showcase
      • Clinical & Research Tools Showcase
      • Clinical Dx Showcase
      • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
      • Digital Health/Health and Wellness
      • Digital Phenotyping
      • Diversity in Precision Medicine
      • Drug Development (PPPs)
      • Early Days of Life Sequencing
      • Emerging Technologies in PM
      • Emerging Therapeutic Showcase
      • FDA Efforts to Accelerate PM
      • Gene Editing / CRISPR
      • Genomic Profiling Showcase
      • Immunotherapy Sessions & Showcase
      • Implementation into Health Care Delivery
      • Large Scale Bio-data Resources to Support Drug Development (PPPs)
      • Microbial Profiling Showcase
      • Microbiome
      • Neoantigens
      • Next-Gen. Workforce of PM
      • Non-Clinical Services Showcase
      • Pharmacogenomics
      • Point-of Care Dx Platform
      • Precision Public Health
      • Rare Disease Diagnosis
      • Resilience
      • Robust Clinical Decision Support Tools
      • Wellness and Aging Showcase
  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 2000+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine
Get Updates
Sign up for occasional updates on upcoming conferences, news, and other information.
We respect your privacy and will never share your email with anyone.
Something went wrong, please verify your input.
Thank you for signing up!

Get Exclusive Access to the Top PMWC Talks

To receive the most comprehensive news and updates from the field of precision medicine, subscribe to the newsletter here.

Bonus for suscribing, you will get the access code for the top 3 talk videos from January's Precision Medicine World Conference.

You have successfully subscribed, you can access the talks here.